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The general view of cancer progression is based on a gradual
evolutionary process, involving a continuous acquisition of genetic
changes in individual cells with successive subclonal selection and
expansion.1 However, whole-genome sequencing (WGS) in cancer
has led to discover the chromothripsis phenomenon, in which
focal regions of the genome undergo extensive chromosome
fragmentation and reorganization causing structural genomic
complexity in some tumor cells.2 Chromothripsis was ﬁrst
described in a chronic lymphocytic leukemia (CLL) patient with
aggressive disease.2 Subsequent WGS has revealed chromothripsis
in other tumor types, mostly associated with aggressive clinical
courses.2–5 Breakpoint characteristics suggest that multiple
regional lesions occur by a single catastrophic mitotic event
acting as a driver of tumor initiation, activating oncogenes and
disrupting tumor-suppressor genes randomly.2–5 However, an
evaluation of the genetic evolution of a cancer genome with
chromothripsis has not been reported yet, and from a clinical
perspective, much remains to be understood. We present here a
longitudinal analysis over 11 years of evolution of a CLL case
affected by chromothripsis with the goal to answer two main
unsolved questions: (a) is chromothripsis an initiating event or is it
an episode arising from previous alterations? And (b) does
chromothripsis resist successive therapeutic interventions?
We characterized structural variants (SVs) and single-nucleotide
variants (SNVs) by sequencing and molecular approaches in
different samples from a 59-year-old IGHV unmutated CLL patient
(ICGC-CLL code 016) obtained at four time points over 11 years of
clinical evolution. Sample 016-T02 was collected 6 years after
diagnosis, just before starting the ﬁrst treatment due to the
increase of CLL aggressiveness, and analyzed by WGS (Figure 1a).
WGS results showed a proﬁle of complex SVs with similar
characteristics of other previously published cases of chromo-
thripsis.2–5 Although conventional cytogenetic and ﬂuorescence
in situ hybridization analysis showed only a derivative
chromosome formed by 4q (duplicated) and 18q (with 18p
deletion) (Supplementary Table S1), by single-nucleotide poly-
morphism (SNP) array and targeted re-sequencing we conﬁrmed
49 SVs detected by WGS (Supplementary Table S3). Most SVs
showed chromosome geographical localization, with 80% of
breakpoints (involving 35 of 49 SVs) conﬁned to focal points on
chromosomes 1, 6, 10 and 12. A signiﬁcant link between the small
regions and an altered copy-number proﬁle alternating two states
demonstrated the existence of complex genomic rearrangements
consistent with the pattern of chromothripsis2,6 (Figure 1b,
Supplementary Figure S1). The remaining 14/49 SVs affect one
locus each (Supplementary Table S3). In addition, RNA sequencing
showed that the 1.6-Mb deletion on 6p21 lead to a
fusion transcript of UBR2-SPATS1 (Supplementary Figure S2).
Furthermore, we conﬁrmed 13 potentially functional SNVs
previously detected in this sample by exome sequencing7 and
we found one additional somatic de novo SNV (c.G566C:p.R189T)
in ATM (Table 1), validated by RNA and Sanger sequencing
(Supplementary Figure S3). Interestingly, the SNV that generates a
premature stop codon (c.G853T:p.E285X) in NFKBIE, located in
6p21, should lead to the total absence of a functional gene due to
the 1.6-Mb deletion of the other allele.
To determine if chromothripsis was involved in the tumorigen-
esis and survived therapeutic intervention, we analyzed from
the same patient three samples obtained at different time points
(016-T00, 016-T05 and 016-T11) (Figure 1a). These samples were
collected in pre-treatment and two post-treatment phases.
Cytogenetics and ﬂuorescence in situ hybridization analyses,
performed in each stage, showed the same proﬁle of sample
016-T02 (Supplementary Table S1). The 49 additional SVs were
analyzed by SNP array and targeted re-sequencing (Figure 1a). We
also validated the 13 potential deleterious somatic SNVs and the
new mutation in ATM. Only seven non-complex SVs and twelve
SNVs were detected in all samples (Figure 1c, Table 1,
Supplementary Table S3), indicating that they remained during
disease progression and suggesting their potential role in the CLL
initiation. We did not detect the pattern of complex rearrange-
ments in the additional samples (Figure 1c, Supplementary Table
S3, Supplementary Figure S4), demonstrating that chromothripsis
was reversible by treatment and it did not participate in the tumor
development and subsequent relapses. Three additional deletions
(on 2p16, 3p14 and 6p22), a tandem duplication (1q44) and the
NFKBIE mutation were also exclusive of 016-T02, suggesting that
they progressed and disappeared together with the chromothrip-
sis. SNP array did not identify any additional somatic copy-number
alteration (CNA) at any other time point (Supplementary Figure S5),
revealing no other subclonal populations carrying different CNA.
To evaluate whether the SVs exclusive of sample 016-T02 occurred
in the same subclonal population, we analyzed the clonal fraction
(CF) of all of them. We found all in a CF of 40–50%, strongly
suggesting that occurred at the same subpopulation. In contrast,
those SVs common in all time points presented a CF of B90% in
016-T02, indicating that they were present in most tumor cells at
chromothripsis appearance (Supplementary Table S4, Supplementary
Figure S6). This suggests that a subclonal competing population
carrying chromothripsis emerged from a major population of tumor
cells. These results were supported by the SNV frequencies in sample
016-T02, revealing that the tumor was composed by two main
subpopulations corresponding to regions of CF of B50% and
B90%, respectively (Supplementary Figure S9). Interestingly, the
NFKBIE mutation was found in a CF of 48% and the remaining SNVs
of B90% (Supplementary Table S5). This supports that NFKBIE
mutation appeared in the same subpopulation as chromothripsis,
whereas the remaining SNVs were in almost all tumor cells.
Targeted re-sequencing and SNP array performed in all samples
did not allow calculating the CF for the shared CNA. However, CNA
parameters obtained by SNP array for these regions suggested
similar CF along the disease progression (Supplementary Figure
S10). Conversely, targeted re-sequencing enabled a good estimate
of the CF for SNVs in sample 016-T02 (Supplementary Table S6).
Thus, we observed highly similar CF values for SNVs in all samples
and no signs of mutated alleles in sample 016-N09 (Figure 1c,
Supplementary Table S6).
The predominant population of tumor cells observed in sample
016-T02 has been prevailing along disease evolution of patient
016, reappearing even after two lines of treatment and a short
disease-free period, in contrast of previous ﬁndings relating
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chemotherapy-treated CLL with different clonal expansions.8
Therefore, this preponderant clone might entail driver mutations
for the CLL development. Appealing driver alterations could be
the 18p deletion, recently observed in 3% of CLL cases,9 the 6p21
deletion, entailing the formation of fusion transcript UBR2-SPATS1,
and the ATM mutation (R189T), because ATM mutations occur in
12% of CLL cases10 and deletions are associated with high-risk
CLL.9,11,12 The ATM mutation could also explain the rise
of chromothripsis because of its role in regulating DNA-damage
response through p53 signaling. Cells bearing defects in
this pathway should be predisposed to chromothripsis.4
Finally, chromothripsis has been detected in 5% of CLL patients,
most with unmutated IGHV, high-risk CLL genomic aberrations
(11q22 and 17p13 deletions) and/or TP53 mutations.9 Hence,
although patient 016 had no TP53 alterations, the high CF of cells
with the ATM mutation supports its potential functional
implications both in CLL and chromothripsis.
Our study clearly shows that chromothripsis was not the tumor-
initiating event but it participated in the increase of CLL
aggressiveness observed in 016-T02, as subclones carrying
complex SVs were in expansion and competing with a predomi-
nant tumor population. Within the chromothripsis rearrange-
ments, we found a 2-Mb deletion affecting the 6q21 locus,
involved in 6% of CLL and linked to shorter progression-free
survival.9,11,13,14 In addition, we detected a 10q24 deletion
involving NFKB2, also detected in a small percentage of CLL
patients.9 The E285X mutation in NFKBIE was potentially important
for chromothripsis, as the deletion of the other allele in affected
subclones led to the absence of a functional NFKBIE allele.
Interestingly, Nfkbie-knockout mice exhibit increased B-cell
Figure 1. Longitudinal analysis of SVs of case 016 over a period of 11 years of disease evolution. (a) A 59-year-old male was diagnosed with
CLL, IGHV unmutated subtype at stage A0 in 1996. He did not require treatment until 2002, when CLL progressed to stage BII, because of the
development of massive lymph nodes, splenomegaly and constitutional symptoms. He received fludarabine-cyclophosphamide-
mitoxantrone (six cycles), with complete response and negative detection of minimal residual disease (MRD). In 2006, the patient relapsed
(BII), and was retreated with six cycles of fludarabine-cyclophosphamide-mitoxantrone-rituximab, obtaining a complete response, MRD
negative. He was free of disease in 2009 when normal mononuclear cells were collected. After a second relapse (BI) in 2011 with an axillar
bulky lymphadenopathy, the patient received six cycles of rituximab-bendamustine, with excellent response, MRD negative, which is
maintained until December 2012. Somatic SV characterization was done by WGS of samples 016-T02 and 016-N09 (Supplementary Table S2).
Mosaicism analysis of CNAs of sample 016-T02 was done by Illumina HumanOmni1-Quad array (Illumina, Inc., San Diego, CA, USA). Somatic
point mutations analysis of sample 016-T02 was performed as described by exome sequencing7 and using an additional in-house pipeline.
Validation of somatic SVs and point mutations in all samples was done by a targeted re-sequencing approach (Agilent SureSelect Target
Enrichment; Agilent Technologies, Santa Clara, CA, USA) and by Affymetrix 6.0 SNP array (Affymetrix 6.0; Affymetrix, Santa Clara, CA, USA).
Detection of fusion transcripts of RNA in sample 016-T02 were performed by RNA sequencing.7 Further detailed information is provided in
Supplementary Methods. (b) Circos representing the SVs detected in sample 016-T02, before starting treatment, in consistence with the
chromothripsis pattern. (c) Circos representing the SVs detected in pre-treatment (016-T00) and post-treatment (016-T05 and 016-T11)
samples. (d) Evolution of cancer cell CF over time for SNVs and chromothripsis rearrangements. Smoothed solid curves represent the average
profile of the time evolution of cancer cell percentages of the mutations detected in all time points (black) and only in sample 016-T02 (red).
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proliferation and survival,15 supporting its implication in CLL
evolution.
We conﬁrmed the single catastrophic model for chromothripsis,
but we showed that it appeared years after the CLL diagnosis,
rejecting a hypothetic role in the tumor initiation. Our data
suggest that chromothripsis might have been the consequence of
previous alterations expanded from an early leukemia cell, which
would have led to chromosome instability associated with defects
in DNA repair. The complex rearrangements of chromothripsis
added on a previous tumor cell carrying expanded alterations
might have conferred a selective advantage to the subclonal
population increasing its malignancy, providing a more aggressive
CLL phenotype.
Our ﬁndings also revealed that chromothripsis subclones did
not survive chemotherapy and that it has not reappeared in a
period of 10 years, having therefore no apparent implications for
patient prognosis. This differs from previous data strongly
associating chromothripsis with chemotherapy surviving and/or
poor clinical outcome.2–5 Chemotherapeutic regimens followed
by our case achieved continuously excellent responses, but a
subset of non-chromothripsis alterations led to the relapse of
the CLL phenotype. This indicates that an undetectable
percentage of cells carrying these alterations persisted after
therapy and subsequently expanded.
In summary, our study demonstrates the importance of
analyzing cancer samples at different time points to elucidate
clonal genotypes that could be therapy resistant, which might
help in therapeutic decisions along the CLL clinical course.16 This
is the ﬁrst description of the rise and fall of chromothripsis,
demonstrating that it was a secondary effect of the
genomic instability typical of tumor cells. However, there is the
need of other cases to be analyzed to better understand
the dynamics of chromothripsis and to determine the
exceptionality of our case.
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Table 1. Somatic point mutations in all time-point samples
Chromosome Position Reference Observed Gene Exonic function AA change 016-T00 016-T02 016-T05 016-T11
1 78425887 G A FUBP1 Stopgain SNV NM_003902:c.C1558T:p.Q520X þ þ þ þ
1 186277552 A G PRG4 Nonsynonymous SNV NM_001127710:c.A2299G:p.T767A þ þ þ þ
3 141163154 C T ZBTB38 Nonsynonymous SNV NM_001080412:c.C1924T:p.P642S þ þ þ þ
6 44230329 C A NFKBIE Stopgain SNV NM_004556:c.G853T:p.E285X  þ  
6 132892234 A C TAAR6 Nonsynonymous SNV NM_175067:c.A774C:p.K258N þ þ þ þ
6 146264389 T C SHPRH Nonsynonymous SNV NM_001042683:c.A2128G:p.M710V þ þ þ þ
11 108114749 G C ATM Nonsynonymous SNV NM_000051:c.G566C:p.R189T þ þ þ þ
12 21358921 C A SLCO1B1 Nonsynonymous SNV NM_006446:c.C1451A:p.P484H þ þ þ þ
15 45409873 A G DUOXA1 Nonsynonymous SNV NM_144565:c.T1292C:p.V431A þ þ þ þ
16 745751 T C FBXL16 Nonsynonymous SNV NM_153350:c.A806G:p.N269S þ þ þ þ
17 42463002 G A ITGA2B Nonsynonymous SNV NM_000419:c.C491T:p.A164V þ þ þ þ
19 19431945 G A MAU2 Splicing site NA þ þ þ þ
19 56173950 A T U2AF2 Nonsynonymous SNV NM_001012478:c.A569T:p.Q190L þ þ  þ
X 125299321 C A DCAF12L2 Nonsynonymous SNV NM_001013628:c.G587T:p.W196L þ þ þ þ
þ , present;  , absent.
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Toward personalized therapy in AML: in vivo beneﬁt of targeting
aberrant epigenetics in MLL-PTD-associated AML
Leukemia (2013) 27, 2379–2382; doi:10.1038/leu.2013.147
The MLL gene, encoding a transcription factor with histone H3
lysine 4 (H3K4) methyltransferase activity, is mutated via a gain-of-
function intragenic, self-fusion mutation called the Partial Tandem
Duplication (MLL-PTD) in B5% of patients with cytogenetically
normal acute myeloid leukemia (CN-AML) and associates with
poor prognosis.1–4 Although intense therapy such as post-
remission autologous or allogeneic stem cell transplant appears
to improve their outcome,5 adult patients with MLL-PTD-positive
CN-AML still die of the disease, thus suggesting the need for novel
‘personalized’ treatment(s). Unfortunately, no speciﬁc inhibitors
that target the aberrant MLL H3K4 methyltransferase activity are
currently available. Nevertheless, we previously demonstrated an
association of MLL-PTD with increased DNA hypermethylation, an
epigenetic change mediated by DNA methyltransferases (DNMTs)
that leads to aberrant tumor suppressor gene silencing in AML.
We also showed that the combination of epigenetic targeting
agents, a DNA hypomethylating agent (that is, decitabine)
followed by a histone deacetylase inhibitor (HDACi), decreased
the transcript ratio of the MLL-PTD-to-MLL-wild type (WT) alleles
and concurrently induced apoptosis in MLL-PTD-positive blasts.6
However, these results were obtained only with in vitro cultures,
and as such, in vivo validation of this approach is necessary to
move it into the clinic. Thus, we aimed herein to validate the
epigenetics-targeting approach to MLL-PTD AML in an in vivo
mouse model of spontaneous AML that harbors the knocked-in
mutations of Mll-PTD and the receptor tyrosine kinase Flt3-internal
tandem duplication (Flt3-ITD), hereafter referred to as double
knock-in (dKI). This model recapitulates features of the counterpart
human disease.7 Indeed, B30% of MLL-PTD AML patients also
harbor FLT3-ITD and have a poor prognosis.5
The bone marrow (BM) from dKI AML mice exhibited an B1.7-
fold increase in the global DNA methylation index, as measured
using deep-sequencing analysis of methylated DNA captured by
methyl-binding protein (MBD2)8 (Figure 1a, P¼ 0.017, t-test, see
Supplementary Material for all methods). Correspondingly,
Dnmt1, 3a and 3b mRNA levels were increased in leukemia
cells relative to single KIs or WT controls (1.5-, 2.3- and 5.3-fold,
respectively, Pp0.0002) (Figures 1b–d). These data establish
that aberrant DNA hypermethylation occurred in the dKI AML
model, thereby recapitulating epigenetic features of the human
AML counterpart6,9 and supporting this model for in vivo targeting
of aberrant epigenetics for the treatment of MLL-PTD-driven AML.
Thus, we designed a study that combined a DNA hypomethylating
agent, 50-aza-20-deoxycytidine (5AD), and a histone deacetylating
agent AR42. 5AD is a nucleoside analog with a proven clinical
activity in AML patients when given at a relatively low dose
(20mg/m2/day 10 days).10 AR42 is a novel HDACi with a proven
anti-leukemia activity that is being tested in an early clinical
trial at our institution.11–13 To establish optimal conditions and
demonstrate anti-leukemia activity of the combination, we ﬁrst
tested AR42 in combination with 5AD on the MLL-PTDþ human
EOL1 cell line, as well as on primary mouse dKI BM blasts cultured
ex vivo in the presence of recombinant rat stem cell factor and
murine interleukin-3. Cells were incubated with the sequential
combination of 5AD followed by AR42, and exhibited signiﬁcant
growth inhibition and increased apoptosis (Figures 2a and b,
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